FOLH1 and prostate carcinoma: Hypothetically, FDG+/PSMA- findings in prostate carcinoma patients could serve as a surrogate for MUC1 expression and, hence, for the selection of mCRPC patients that might benefit from combined MUC1 and PSMA targeted therapy.